{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:55:33Z","timestamp":1784782533884,"version":"3.55.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.coi.2025.102661","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T05:49:51Z","timestamp":1759297791000},"page":"102661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["COVID-19 and inflammatory bowel disease \u2014 what to know"],"prefix":"10.1016","volume":"97","author":[{"given":"Anne","family":"Godat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Chistoforidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Greuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102661_bib1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1146\/annurev-immunol-030409-101225","article-title":"Inflammatory bowel disease","volume":"28","author":"Kaser","year":"2010","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.coi.2025.102661_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature10209","article-title":"Genetics and pathogenesis of inflammatory bowel disease","volume":"474","author":"Khor","year":"2011","journal-title":"Nature"},{"issue":"Suppl A","key":"10.1016\/j.coi.2025.102661_bib3","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102661_bib4","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102661_bib5","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102661_bib6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","article-title":"Understanding and preventing the global increase of inflammatory bowel disease","volume":"152","author":"Kaplan","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102661_bib7","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.15585\/mmwr.mm6542a3","article-title":"Prevalence of inflammatory bowel disease among adults aged \u226518 years \u2013 United States, 2015","volume":"65","author":"Dahlhamer","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.coi.2025.102661_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231218615","article-title":"Crossing barriers: the burden of inflammatory bowel disease across Western Europe","volume":"16","author":"Kumar","year":"2023","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.coi.2025.102661_bib9","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102661_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40291-023-00678-7","article-title":"The genetics of inflammatory bowel disease","volume":"28","author":"El Hadad","year":"2024","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.coi.2025.102661_bib11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.14309\/ajg.0000000000002180","article-title":"The contribution of genetic risk and lifestyle factors in the development of adult-onset inflammatory bowel disease: a prospective cohort study","volume":"118","author":"Sun","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102661_bib12","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","article-title":"The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study","volume":"96","author":"Bernstein","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102661_bib13","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2005.06.021","article-title":"The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study","volume":"129","author":"Bernstein","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102661_bib14","first-page":"297","article-title":"Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis","volume":"125","author":"Mendoza","year":"2005","journal-title":"Med Clin"},{"key":"10.1016\/j.coi.2025.102661_bib15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00054725-200405000-00005","article-title":"Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study","volume":"10","author":"Ricart","year":"2004","journal-title":"Inflamm Bowel Dis"},{"issue":"Pt 2","key":"10.1016\/j.coi.2025.102661_bib16","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/0016-5085(79)90391-3","article-title":"National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications","volume":"77","author":"Rankin","year":"1979","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102661_bib17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0889-8553(01)00019-X","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"31","author":"Su","year":"2002","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.coi.2025.102661_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004836-199607000-00009","article-title":"Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients","volume":"23","author":"Veloso","year":"1996","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.coi.2025.102661_sbref19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102661_bib20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/ecco-jcc\/jjy191","article-title":"The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis and therapy","volume":"13","author":"Hedin","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.coi.2025.102661_sbref21","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.coi.2025.102661_sbref22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102661_sbref23","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102661_sbref24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/path.5471","article-title":"Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)","volume":"251","author":"Bourgonje","year":"2020","journal-title":"J Pathol"},{"key":"10.1016\/j.coi.2025.102661_bib25","doi-asserted-by":"crossref","first-page":"e695","DOI":"10.1093\/cid\/ciaa1419","article-title":"Risk factors for coronavirus disease 2019 (COVID-19)-associated hospitalization: COVID-19-associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System","volume":"72","author":"Ko","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coi.2025.102661_bib26","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(21)02796-3","article-title":"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21","volume":"399","author":"Collaborators","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102661_bib27","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.amjgastroenterol.2003.11.002","article-title":"Maintenance therapy for inflammatory bowel disease","volume":"98","author":"Feagan","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102661_bib28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41575-024-01035-7","article-title":"Understanding the therapeutic toolkit for inflammatory bowel disease","volume":"22","author":"Vieujean","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102661_bib29","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1053\/j.gastro.2021.09.078","article-title":"Breaking through the therapeutic ceiling: what will it take?","volume":"162","author":"Raine","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102661_bib30","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102661_bib31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102661_bib32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cgh.2019.02.044","article-title":"Comparative risk of serious infections with biologic and\/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102661_bib33","doi-asserted-by":"crossref","unstructured":"Axelrad JE et\u00a0al.: 204 Risk of serious and opportunistic infections in patients with ulcerative colitis treated with biologic and small molecule therapies: a nationwide study.\u00a0Digestive Disease Week; 2025.","DOI":"10.1016\/S0016-5085(25)01090-X"},{"key":"10.1016\/j.coi.2025.102661_sbref33","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"Suppl\u00a03","key":"10.1016\/j.coi.2025.102661_sbref34","doi-asserted-by":"crossref","first-page":"S798","DOI":"10.1093\/ecco-jcc\/jjaa160","article-title":"Inflammatory bowel disease management during the COVID-19 outbreak: the ten do's and don'ts from the ECCO-COVID taskforce","volume":"14","author":"Magro","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.coi.2025.102661_bib36","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/ibd\/izaa303","article-title":"Characteristics and outcomes of IBD patients with COVID-19 on tofacitinib therapy in the SECURE-IBD Registry","volume":"27","author":"Agrawal","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.coi.2025.102661_bib37","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1093\/ibd\/izab299","article-title":"Mesalazine in inflammatory bowel disease and COVID-19: hospitalization and adverse in-hospital outcomes based on nationwide data","volume":"28","author":"Kjeldsen","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.coi.2025.102661_sbref37","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1053\/j.gastro.2021.09.011","article-title":"Impact of medications on COVID-19 outcomes in inflammatory bowel disease: analysis of more than 6000 patients from an international registry","volume":"162","author":"Ungaro","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102661_bib39","article-title":"Steroid therapy for COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"91","author":"Boppana","year":"2021","journal-title":"Monaldi Arch Chest Dis"},{"key":"10.1016\/j.coi.2025.102661_bib40","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025719","article-title":"Corticosteroid therapy for COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"100","author":"Pulakurthi","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.coi.2025.102661_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108121","article-title":"Effectiveness of corticosteroids to treat severe COVID-19: a systematic review and meta-analysis of prospective studies","volume":"100","author":"Li","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.coi.2025.102661_sbref41","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.cgh.2020.08.003","article-title":"Systematic review on inflammatory bowel disease patients with coronavirus disease 2019: it is time to take stock","volume":"18","author":"D'Amico","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102661_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-25429-2","article-title":"Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis","volume":"12","author":"Abdulla","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2025.102661_sbref43","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/ibd\/izab236","article-title":"COVID-19 and outcomes in patients with inflammatory bowel disease: systematic review and meta-analysis","volume":"28","author":"Tripathi","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.coi.2025.102661_sbref44","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastha.2024.10.021","article-title":"A systematic review and meta-analysis: adverse inflammatory bowel disease outcomes following acute COVID-19","volume":"4","author":"Vitus","year":"2025","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.coi.2025.102661_sbref45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjgast-2020-000581","article-title":"Depression, anxiety and stress among patients with inflammatory bowel disease during the COVID-19 pandemic: Australian National Survey","volume":"8","author":"Cheema","year":"2021","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.coi.2025.102661_sbref46","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2023.2295979","article-title":"SARS-CoV-2 vaccination in inflammatory bowel disease patients is not associated with flares: a retrospective single-centre Swiss study","volume":"56","author":"Rossier","year":"2024","journal-title":"Ann Med"},{"key":"10.1016\/j.coi.2025.102661_bib48","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S2468-1253(20)30119-9","article-title":"Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period","volume":"5","author":"Iacucci","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102661_bib49","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3748\/wjg.v27.i11.1022","article-title":"How to manage inflammatory bowel disease during the COVID-19 pandemic: a guide for the practicing clinician","volume":"27","author":"Chebli","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102661_bib50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00000658-200001000-00006","article-title":"Risk factors for surgery and postoperative recurrence in Crohn's disease","volume":"231","author":"Bernell","year":"2000","journal-title":"Ann Surg"},{"key":"10.1016\/j.coi.2025.102661_sbref50","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/TA.0000000000003859","article-title":"Is perioperative COVID-19 really associated with worse surgical outcomes? A nationwide COVIDSurg propensity-matched analysis","volume":"94","author":"Argandykov","year":"2023","journal-title":"J Trauma Acute Care Surg"},{"key":"10.1016\/j.coi.2025.102661_bib52","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/anae.16001","article-title":"Postoperative mortality and complications in patients with and without pre-operative SARS-CoV-2 infection: a service evaluation of 24 million linked records using OpenSAFELY","volume":"78","author":"McInerney","year":"2023","journal-title":"Anaesthesia"},{"key":"10.1016\/j.coi.2025.102661_sbref52","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41575-020-0294-8","article-title":"Management of IBD during the COVID-19 outbreak: resetting clinical priorities","volume":"17","author":"Danese","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102661_bib54","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/ibd\/izad055","article-title":"Long-term impact of the COVID-19 pandemic on inflammatory bowel disease healthcare utilization: a 2-year nationwide update","volume":"30","author":"Derks","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.coi.2025.102661_bib55","article-title":"The impact of COVID-19 on inflammatory bowel disease surgery: a systematic review","author":"Couch","year":"2025","journal-title":"Ann R Coll Surg Engl"},{"key":"10.1016\/j.coi.2025.102661_bib56","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s13304-021-01119-y","article-title":"Inflammatory bowel disease patients requiring surgery can be treated in referral centres regardless of the COVID-19 status of the hospital: results of a multicentric European study during the first COVID-19 outbreak (COVIBD-Surg)","volume":"73","author":"Rottoli","year":"2021","journal-title":"Updates Surg"},{"key":"10.1016\/j.coi.2025.102661_bib57","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.cgh.2022.02.017","article-title":"International consensus recommendations for eosinophilic gastrointestinal disease nomenclature","volume":"20","author":"Dellon","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102661_bib58","first-page":"1419","article-title":"Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings","volume":"124","author":"Straumann","year":"1994","journal-title":"Schweiz Med Wochenschr"},{"key":"10.1016\/j.coi.2025.102661_bib59","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/j.gastro.2017.06.067","article-title":"Epidemiology and natural history of eosinophilic esophagitis","volume":"154","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102661_bib60","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cgh.2024.09.031","article-title":"Prevalence and costs of eosinophilic esophagitis in the United States","volume":"23","author":"Thel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102661_bib61","doi-asserted-by":"crossref","first-page":"697","DOI":"10.14309\/ajg.0000000000001658","article-title":"Eosinophilic gastrointestinal diseases beyond eosinophilic esophagitis","volume":"117","author":"Dellon","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102661_bib62","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/MPG.0000000000000865","article-title":"Prevalence of eosinophilic gastritis, gastroenteritis, and colitis: estimates from a national administrative database","volume":"62","author":"Jensen","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.coi.2025.102661_bib63","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.cgh.2017.05.050","article-title":"Prevalence of eosinophilic gastroenteritis and colitis in a population-based study, from 2012 to 2017","volume":"15","author":"Mansoor","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102661_bib64","doi-asserted-by":"crossref","first-page":"984","DOI":"10.14309\/ajg.0000000000000228","article-title":"Increasing rates of diagnosis, substantial co-occurrence, and variable treatment patterns of eosinophilic gastritis, gastroenteritis, and colitis based on 10-year data across a multicenter consortium","volume":"114","author":"Pesek","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102661_bib65","doi-asserted-by":"crossref","DOI":"10.1097\/MEG.0000000000001909","article-title":"Eosinophilic esophagitis: is the Th2 inflammation protective against the severe form of COVID-19?","volume":"32","author":"Franceschini","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102661_sbref65","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaip.2021.10.019","article-title":"Eosinophilic esophagitis patients are not at increased risk of severe COVID-19: a report from a global registry","volume":"10","author":"Zevit","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.coi.2025.102661_bib67","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/jgh3.12969","article-title":"The impact of COVID-19 on Japanese patients with eosinophilic gastrointestinal disorders during the vaccination era","volume":"7","author":"Fujiwara","year":"2023","journal-title":"JGH Open"},{"key":"10.1016\/j.coi.2025.102661_bib68","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3390\/biomedicines13030674","article-title":"Severe asthma and active SARS-CoV-2 infection: insights into biologics","volume":"13","author":"Manti","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.coi.2025.102661_bib69","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/j.jinf.2023.10.015","article-title":"The effect of dupilumab on clinical outcomes in patients with COVID-19: a meta-analysis","volume":"87","author":"Ao","year":"2023","journal-title":"J Infect"},{"key":"10.1016\/j.coi.2025.102661_bib70","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc'h","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.coi.2025.102661_bib71","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/cid\/ciac745","article-title":"Dupilumab use is associated with protection from coronavirus disease 2019 mortality: a retrospective analysis","volume":"76","author":"Donlan","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coi.2025.102661_bib72","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaip.2021.10.050","article-title":"COVID-19 symptoms are attenuated in moderate-to-severe atopic dermatitis patients treated with dupilumab","volume":"10","author":"Ungar","year":"2022","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:39:46Z","timestamp":1775032786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525001372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":72,"alternative-id":["S0952791525001372"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102661","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 and inflammatory bowel disease \u2014 what to know","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102661"}}